Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Herakles Kritikos"'
Autor:
V Vazgiourakis, Maria I. Zervou, George N. Goulielmos, Eva Choustoulaki, Eleni Krasoudaki, Amalia Raptopoulou, Dimitrios T. Boumpas, Herakles Kritikos, Prodromos Sidiropoulos, Eleni Petraki
Publikováno v:
Human Immunology. 69:567-571
Summary Rheumatoid arthritis (RA) is a multifactorial disease that is increasing in incidence worldwide. It is associated with a complex mode of inheritance, with many genes being involved in the development and progression of the disease. Genome-wid
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a2f5b4fa77abcb0d824d89d2eb545a7
https://doi.org/10.1016/j.humimm.2008.06.006
https://doi.org/10.1016/j.humimm.2008.06.006
Autor:
G. Bertsias, Prodromos Sidiropoulos, Stylianos A Karvounaris, Emmanuel S. Ganotakis, John A. Papadakis, Dimitrios T. Boumpas, Elias K. Spanakis, Herakles Kritikos
Publikováno v:
Annals of the Rheumatic Diseases. 66:28-33
Objectives: Patients with rheumatoid arthritis have an increased risk for cardiovascular disease (CVD). The prevalence of metabolic syndrome (MetS)—a major contributor to CVD—in a cohort of patients with rheumatoid arthritis and its relationship
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::42531ab57b465ff3b95284b27a7e27aa
https://doi.org/10.1136/ard.2006.053488
https://doi.org/10.1136/ard.2006.053488
Publikováno v:
Drug Discovery Today: Therapeutic Strategies. 1:375-382
Some patients with severe lupus erythematosus do not respond to conventional immunosuppression (usually a combination of corticosteroids with cyclophosphamide) or develop severe side-effects from such treatment, necessitating the search for alternati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::768b0b18d37b4db7234e8eab0c480efa
https://doi.org/10.1016/j.ddstr.2004.11.011
https://doi.org/10.1016/j.ddstr.2004.11.011
Publikováno v:
Current Rheumatology Reports. 2:423-429
This article summarizes recent advances in the management of various vasculitic syndromes and discusses potential new therapies based on a better understanding of their pathogenesis and natural history. Current efforts for optimization of testing for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::351615f86af1dbdd385fa1e54e8880df
https://doi.org/10.1007/s11926-000-0043-5
https://doi.org/10.1007/s11926-000-0043-5
Autor:
Amalia Raptopoulou, Christianna Choulaki, Clio Mamalaki, Eva D. Papadimitraki, Herakles Kritikos, George Bertsias, Magda Nakou, Dimitris Kardassis, Maria Tzardi, Dimitrios T. Boumpas, Prodromos Sidiropoulos, George N. Goulielmos
Publikováno v:
Arthritis and rheumatism. 60(1)
Objective A putative regulatory intronic polymorphism (PD1.3) in the programmed death 1 (PD-1) gene, a negative regulator of T cells involved in peripheral tolerance, is associated with increased risk for systemic lupus erythematosus (SLE). We undert
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16e6323c538ea915c1bba185cf3cecc8
https://pubmed.ncbi.nlm.nih.gov/19116915
https://pubmed.ncbi.nlm.nih.gov/19116915
Autor:
O N Manousos, Ioannis E. Koutroubakis, Stilianos M. Spanoudakis, Herakles Kritikos, Efthimia Petinaki, Andreas N. Kapsoritakis, Ioannis A. Mouzas, Elias A. Kouroumalis
Publikováno v:
Europe PubMed Central
Background Common aetiopathogenic factors may explain the association of ulcerative colitis with autoimmune disorders such as systemic lupus erythematosus. Patients We report two cases of ulcerative colitis associated with idiopathic systemic lupus e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::877964dd662357a77c73623289bf9a4a
https://pubmed.ncbi.nlm.nih.gov/9619394
https://pubmed.ncbi.nlm.nih.gov/9619394
Autor:
Helen A. Papadaki, George Bertsias, Eva D. Papadimitraki, Prodromos Sidiropoulos, Amalia Raptopoulou, Dimitrios T. Boumpas, Magda Nakou, Georgios Katsikas, Helen Koutala, Herakles Kritikos
Publikováno v:
Arthritis Research & Therapy
Introduction Bone marrow (BM) is an immunologically privileged site where activated autoantibody-producing B cells may survive for prolonged periods. We investigated the effect of rituximab (anti-CD20 mAb) in peripheral blood (PB) and BM B-cell and T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f69af53b45b5fdaeefd18f986ae10239